We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy.
- Authors
Desai, Milind Y.; Ali, Adel Hajj
- Abstract
Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.
- Subjects
DRUG efficacy; CLINICAL trials; HEALTH services accessibility; CARDIAC hypertrophy; MYOSIN; HEART septum; AMINES; CARDIOVASCULAR agents; CHEMICAL inhibitors; EVALUATION
- Publication
Heart International, 2023, Vol 17, Issue 1, p2
- ISSN
1826-1868
- Publication type
Article
- DOI
10.17925/HI.2023.17.1.2